Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytosorbents

0.9309
+0.03774.22%
Volume:20.35K
Turnover:18.95K
Market Cap:58.28M
PE:-3.24
High:0.9418
Open:0.9394
Low:0.9147
Close:0.8932
52wk High:1.61
52wk Low:0.7101
Shares:62.61M
Float Shares:54.95M
Volume Ratio:0.09
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2876
EPS(LYR):-0.3806
ROE:-96.25%
ROA:-20.46%
PB:4.01
PE(LYR):-2.45

Loading ...

Cytosorbents Corp reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
12 hours ago

BRIEF-CytoSorbents Q2 Revenue USD 9.617 Million

Reuters
·
18 hours ago

CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

Reuters
·
18 hours ago

Cytosorbents Q2 Product Gross Margin 70.9%

THOMSON REUTERS
·
18 hours ago

Cytosorbents Corp: Qtrly Adj EPS $-0.05

THOMSON REUTERS
·
18 hours ago

Cytosorbents Corp expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
Aug 06

CytoSorbents Corporation to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 29

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jul 22

BRIEF-Cytosorbents Provides U.S. FDA And Health Canada Regulatory Update For Drugsorb-Atr

Reuters
·
Jul 02

CytoSorbents Corporation Awaits Final Regulatory Decisions for DrugSorb-ATR in U.S. and Canada Following Appeals Process

Reuters
·
Jul 02

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jun 25

CytoSorbents files appeal with FDA for review of request for DrugSorb-ATR

TIPRANKS
·
Jun 24

CytoSorbents Corporation Files Appeal with U.S. FDA for Review of DrugSorb-ATR Device for CABG Surgery Patients

Reuters
·
Jun 24

CytoSorbents Corporation Conducted Annual Stockholders Meeting

Reuters
·
Jun 14

Cytosorbents Announces Expiration of Series B Warrants

TIPRANKS
·
Jun 12

CytoSorbents Reports Q1 2025 Product Sales of $8.7M, Marking 3% Decrease Year-Over-Year, Despite Strong International Performance

Reuters
·
Jun 05

CytoSorbents Corporation to Participate in Jefferies Global Healthcare Conference in New York

Reuters
·
May 29

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 16

Cytosorbents Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
May 15

CytoSorbents Reports Q1 2025 Revenue Drop of 3%, Operating Loss Improves by 17%

Reuters
·
May 15